Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

Eli Lilly has revealed the location of the second of its four large-scale manufacturing facilities that it plans to build in the U.S., selecting Houston as home to a $6.5 billion plant that will ...

Part of AbbVie’s vow to invest $100 billion in the U.S. over the next decade, the two Illinois facilities will make active ingredients for next-generation neuroscience and obesity drugs when they ...

A rendering of the $5 billion manufacturing facility that Eli LIlly plans to build in Virginia's Goochland County near Richmond. The planned manufacturing plant will be the company's first-ever ...

Eli Lilly and Company (Lilly) plans to construct an active pharmaceutical ingredient (API) manufacturing facility, totaling around 1 million square feet, in Harris County, Texas. According to news ...

BEIJING--(BUSINESS WIRE)-- Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive Asset Purchase Agreement to acquire the ...